Literature DB >> 23250948

The polysaccharide capsule of Campylobacter jejuni modulates the host immune response.

Alexander C Maue1, Krystle L Mohawk, David K Giles, Frédéric Poly, Cheryl P Ewing, Yuening Jiao, Ginyoung Lee, Zuchao Ma, Mario A Monteiro, Christina L Hill, Jason S Ferderber, Chad K Porter, M Stephen Trent, Patricia Guerry.   

Abstract

Campylobacter jejuni is a major cause of bacterial diarrheal disease worldwide. The organism is characterized by a diversity of polysaccharide structures, including a polysaccharide capsule. Most C. jejuni capsules are known to be decorated nonstoichiometrically with methyl phosphoramidate (MeOPN). The capsule of C. jejuni 81-176 has been shown to be required for serum resistance, but here we show that an encapsulated mutant lacking the MeOPN modification, an mpnC mutant, was equally as sensitive to serum killing as the nonencapsulated mutant. A nonencapsulated mutant, a kpsM mutant, exhibited significantly reduced colonization compared to that of wild-type 81-176 in a mouse intestinal colonization model, and the mpnC mutant showed an intermediate level of colonization. Both mutants were associated with higher levels of interleukin 17 (IL-17) expression from lamina propria CD4(+) cells than from cells from animals infected with 81-176. In addition, reduced levels of Toll-like receptor 4 (TLR4) and TLR2 activation were observed following in vitro stimulation of human reporter cell lines with the kpsM and mpnC mutants compared to those with wild-type 81-176. The data suggest that the capsule polysaccharide of C. jejuni and the MeOPN modification modulate the host immune response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250948      PMCID: PMC3584872          DOI: 10.1128/IAI.01008-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

1.  A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176.

Authors:  D J Bacon; C M Szymanski; D H Burr; R P Silver; R A Alm; P Guerry
Journal:  Mol Microbiol       Date:  2001-05       Impact factor: 3.501

2.  Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni.

Authors:  D Linton; M Gilbert; P G Hitchen; A Dell; H R Morris; W W Wakarchuk; N A Gregson; B W Wren
Journal:  Mol Microbiol       Date:  2000-08       Impact factor: 3.501

3.  Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro.

Authors:  Patricia Guerry; Christine M Szymanski; Martina M Prendergast; Thomas E Hickey; Cheryl P Ewing; Dawn L Pattarini; Anthony P Moran
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity.

Authors:  A V Karlyshev; D Linton; N A Gregson; A J Lastovica; B W Wren
Journal:  Mol Microbiol       Date:  2000-02       Impact factor: 3.501

5.  Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells.

Authors:  Alexandra Unkmeir; Ulrike Kämmerer; Anne Stade; Claudia Hübner; Sabine Haller; Annette Kolb-Mäurer; Matthias Frosch; Guido Dietrich
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

6.  Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni.

Authors:  P Guerry; C P Ewing; T E Hickey; M M Prendergast; A P Moran
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Prevalence of Campylobacter fetus subsp. jejuni in healthy populations in southern India.

Authors:  D P Rajan; V I Mathan
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

8.  Experimental Campylobacter jejuni infection of adult mice.

Authors:  M J Blaser; D J Duncan; G H Warren; W L Wang
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

9.  Isolation of Campylobacter fetus subsp. jejuni from Bangladeshi children.

Authors:  M J Blaser; R I Glass; M I Huq; B Stoll; G M Kibriya; A R Alim
Journal:  J Clin Microbiol       Date:  1980-12       Impact factor: 5.948

Review 10.  Interactions between the microbiota and the immune system.

Authors:  Lora V Hooper; Dan R Littman; Andrew J Macpherson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

View more
  37 in total

Review 1.  Insights into Campylobacter jejuni colonization of the mammalian intestinal tract using a novel mouse model of infection.

Authors:  Martin Stahl; Bruce A Vallance
Journal:  Gut Microbes       Date:  2015-04-01

Review 2.  Update on the burden of Campylobacter in developing countries.

Authors:  James A Platts-Mills; Margaret Kosek
Journal:  Curr Opin Infect Dis       Date:  2014-10       Impact factor: 4.915

Review 3.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

4.  Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella.

Authors:  Renee M Laird; Zuchao Ma; Nelum Dorabawila; Brittany Pequegnat; Eman Omari; Yang Liu; Alexander C Maue; Steven T Poole; Milton Maciel; Kavyashree Satish; Christina L Gariepy; Nina M Schumack; Annette L McVeigh; Frédéric Poly; Cheryl P Ewing; Michael G Prouty; Mario A Monteiro; Stephen J Savarino; Patricia Guerry
Journal:  Vaccine       Date:  2018-09-27       Impact factor: 3.641

5.  The Helical Shape of Campylobacter jejuni Promotes In Vivo Pathogenesis by Aiding Transit through Intestinal Mucus and Colonization of Crypts.

Authors:  Martin Stahl; Emilisa Frirdich; Jenny Vermeulen; Yuliya Badayeva; Xiaoxia Li; Bruce A Vallance; Erin C Gaynor
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

6.  Phase-Variable Changes in the Position of O-Methyl Phosphoramidate Modifications on the Polysaccharide Capsule of Campylobacter jejuni Modulate Serum Resistance.

Authors:  Brittany Pequegnat; Renee M Laird; Cheryl P Ewing; Christina L Hill; Eman Omari; Frederic Poly; Mario A Monteiro; Patricia Guerry
Journal:  J Bacteriol       Date:  2017-06-27       Impact factor: 3.490

7.  Coadministration of the Campylobacter jejuni N-Glycan-Based Vaccine with Probiotics Improves Vaccine Performance in Broiler Chickens.

Authors:  H Nothaft; M E Perez-Muñoz; G J Gouveia; R M Duar; J J Wanford; L Lango-Scholey; C G Panagos; V Srithayakumar; G S Plastow; C Coros; C D Bayliss; A S Edison; J Walter; C M Szymanski
Journal:  Appl Environ Microbiol       Date:  2017-11-16       Impact factor: 4.792

8.  Key Role of Capsular Polysaccharide in the Induction of Systemic Infection and Abortion by Hypervirulent Campylobacter jejuni.

Authors:  Orhan Sahin; Samantha A Terhorst; Eric R Burrough; Zhangqi Shen; Zuowei Wu; Lei Dai; Yizhi Tang; Paul J Plummer; Ju Ji; Michael J Yaeger; Qijing Zhang
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

9.  Comparison of predicted epimerases and reductases of the Campylobacter jejuni D-altro- and L-gluco-heptose synthesis pathways.

Authors:  Matthew McCallum; Gary S Shaw; Carole Creuzenet
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

10.  Epidemiology of Campylobacter Infections among Children in Egypt.

Authors:  Rebecca Sainato; Atef ElGendy; Frédéric Poly; Janelle Kuroiwa; Patricia Guerry; Mark S Riddle; Chad K Porter
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.